 |
15 Diseases |  |
7 Trials |
|
7 Trials |  |
200 News |  |
| 1234» |
- | Trial completion, Enrollment change: Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders (clinicaltrials.gov) - Dec 13, 2024
P=N/A, N=190, Completed, Sponsor: Peter Kovacs MD
Recruiting --> Completed | N=700 --> 190
- | progesterone / Generic mfg.
Journal: Vaginal micronized progesterone on preventing luteinizing hormone untimely surge in ART cycles: A prospective proof-of-concept study. (Pubmed Central) - Dec 3, 2024
Recruiting --> Completed | N=700 --> 190 Progestin-Primed Ovarian Stimulation with micronized vaginal progesterone seems to be a compelling choice for preventing premature ovulation without compromising oocyte quality in women undergoing ovarian stimulation.
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring
Journal: Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations. (Pubmed Central) - Sep 14, 2024
Progestin-Primed Ovarian Stimulation with micronized vaginal progesterone seems to be a compelling choice for preventing premature ovulation without compromising oocyte quality in women undergoing ovarian stimulation. Highly purified human menopausal gonadotropin (HP-hMG [Menopur
- | Menopur (menotropin) / Ferring, Follistim AQ Cartridge (follitropin beta) / Organon, Bravelle (urofollitropin) / Ferring
Biomarker, Trial completion date, Adverse events: HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - Jul 3, 2024
P4, N=796, Completed, Sponsor: Lund University
Highly purified human menopausal gonadotropin (HP-hMG [Menopur Trial completion date: Dec 2020 --> May 2024
- ||||||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Trial completion, Enrollment change: Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation (clinicaltrials.gov) - Feb 18, 2024
P=N/A, N=772, Completed, Sponsor: Clinique Ovo
Trial completion date: Dec 2020 --> May 2024 Active, not recruiting --> Completed | N=390 --> 772
- | Menopur (menotropin) / Ferring, NN1213 / Novo Nordisk
Enrollment open, Trial completion date, Trial primary completion date: HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients (clinicaltrials.gov) - Oct 30, 2023
P4, N=150, Recruiting, Sponsor: Mansoura University
Active, not recruiting --> Completed | N=390 --> 772 Unknown status --> Recruiting | Trial completion date: Mar 2021 --> Dec 2024 | Trial primary completion date: Jan 2021 --> Dec 2024
- | Menopur (menotropin) / Ferring
Journal: Analysis of Nurse and Patient Preferences for Pre-Filled Pen Devices for Self-Injection of Highly Purified Human Menopausal Gonadotropin (HP-hMG, MENOPUR). (Pubmed Central) - May 23, 2023
The prototype pen was perceived to possess the key attributes considered important for a gonadotropin pen by patients and nurses, including correcting the dose, the ability to self-inject safely and correctly, ease of preparation and use, and an injection which appeared to be as painless as possible. The prototype pen was found to perform well across all key attributes, especially those considered most important in gonadotropin pens, suggesting that it is a user-friendly option for patients undergoing ART.
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring, Cetrotide (cetrorelix) / EMD Serono
Trial completion, Phase classification, Trial completion date: CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) - May 9, 2023
P1/2, N=200, Completed, Sponsor: Lebanese University
The prototype pen was found to perform well across all key attributes, especially those considered most important in gonadotropin pens, suggesting that it is a user-friendly option for patients undergoing ART. Active, not recruiting --> Completed | Phase classification: PN/A --> P1/2 | Trial completion date: Dec 2021 --> May 2023
- || Menopur (menotropin) / Ferring
That looks like the menopur! I did this last year too. You got this! 🤗 (Twitter) - Apr 9, 2023
- |||||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
New trial: Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation (clinicaltrials.gov) - Feb 21, 2023
P=N/A, N=390, Active, not recruiting, Sponsor: Clinique Ovo
- | Menopur (menotropin) / Ferring
Enrollment change, Trial withdrawal, Real-world evidence, Real-world: Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment (clinicaltrials.gov) - Jan 25, 2023
P=N/A, N=0, Withdrawn, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed | Phase classification: PN/A --> P1/2 | Trial completion date: Dec 2021 --> May 2023 N=1000 --> 0 | Not yet recruiting --> Withdrawn
- ||| Menopur (menotropin) / Ferring
Trial completion: A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women (clinicaltrials.gov) - Aug 24, 2022
P1, N=95, Completed, Sponsor: Ferring Pharmaceuticals
N=1000 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- || Menopur (menotropin) / Ferring
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment (clinicaltrials.gov) - Jun 2, 2022
P=N/A, N=1000, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Trial completion date: May 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> Sep 2023
- | Enrollment open: Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders (clinicaltrials.gov) - May 8, 2022
P=N/A, N=700, Recruiting, Sponsor: Peter Kovacs MD
Trial completion date: May 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> Sep 2023 Not yet recruiting --> Recruiting
- |||| Menopur (menotropin) / Ferring, Follistim AQ Cartridge (follitropin beta) / Organon, Bravelle (urofollitropin) / Ferring
Biomarker, Trial completion, Adverse events: HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - Apr 22, 2022
P4, N=796, Completed, Sponsor: Lund University
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Menopur (menotropin) / Ferring
Journal: Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome? (Pubmed Central) - Mar 12, 2022
The differences in treatment outcome, derived by different LH preparations reflect the distinct physiological role of these molecules. Our findings may assist in tailoring a specific gonadotropin regimen when assembling an OS protocol.
- | Trial completion, Trial completion date, Trial primary completion date: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (clinicaltrials.gov) - Feb 17, 2022
P3, N=90, Completed, Sponsor: El Shatby University Hospital for Obstetrics and Gynecology
Our findings may assist in tailoring a specific gonadotropin regimen when assembling an OS protocol. Not yet recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Sep 2021 --> Mar 2021
- ||| Menopur (menotropin) / Ferring
Trial completion, Enrollment change: MEDAM (Menopur Retrospective Data prograM) (clinicaltrials.gov) - Jan 25, 2022
P=N/A, N=11488, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Sep 2021 --> Mar 2021 Recruiting --> Completed | N=8126 --> 11488
- || Menopur (menotropin) / Ferring
Clinical, Observational data, Journal, HEOR: Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany. (Pubmed Central) - Dec 16, 2021
Recruiting --> Completed | N=8126 --> 11488 This large (> 28,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP.
- | Menopur (menotropin) / Ferring
Journal: First pre-filled pen device with highly purified human menopausal gonadotropin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution. (Pubmed Central) - Nov 21, 2021
This large (> 28,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP. The 90% CIs for the geometric mean ratios of serum FSH AUC and C were both within 0.8000 - 1.2500, thus the two formulations are bioequivalent.
- || Menopur (menotropin) / Ferring, Synera (lidocaine 70 mg/tetracaine 70 mg/heated Topical Patch) / Miravo, Eurocept, Galen, Samaritan Pharma
I totally agree 🧊 before menopur is helpful. The rest aren’t as bad. Everyone is different though so if ice before all is your thing.. 👍🏻 . Ice before none 👍🏻. For me, also, I don’t need 30 synera patches and this cuts some cost. But I do use it for the trigger! (Twitter) - Nov 18, 2021
- || progesterone / Generic mfg., Menopur (menotropin) / Ferring
Icing before menopur helps with the burn. Once you get to progesterone shoot for the upper outer corner of the 🍑 and it’s not too bad! Good luck!! (Twitter) - Nov 18, 2021
- || Menopur (menotropin) / Ferring
Trial initiation date: MEDAM (Menopur Retrospective Data prograM) (clinicaltrials.gov) - Nov 14, 2021
P=N/A, N=8126, Recruiting, Sponsor: Ferring Pharmaceuticals
The 90% CIs for the geometric mean ratios of serum FSH AUC and C were both within 0.8000 - 1.2500, thus the two formulations are bioequivalent. Initiation date: May 2021 --> Nov 2021
- ||| Menopur (menotropin) / Ferring
Enrollment open: A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women (clinicaltrials.gov) - Nov 9, 2021
P1, N=88, Recruiting, Sponsor: Ferring Pharmaceuticals
Initiation date: May 2021 --> Nov 2021 Not yet recruiting --> Recruiting
- | Menopur (menotropin) / Ferring
Preclinical, Journal: Two human menopausal gonadotropin preparations display different early signalling in vitro. (Pubmed Central) - Nov 4, 2021
This drug-specific activation of intracellular signaling pathways is consistent with the molecular composition of these preparations and impacts downstream progesterone and estradiol production, with Menopur® more potent than Meriofert® in inducing the synthesis of both the steroids. These findings are suggestive of distinct in vivo activities of these preparation, but require cautious interpretation and further validation from clinical studies.
- | New trial: Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders (clinicaltrials.gov) - Nov 2, 2021
P=N/A, N=700, Not yet recruiting, Sponsor: Peter Kovacs MD
- ||||||| Menopur (menotropin) / Ferring
Trial completion: CLARA: Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Sep 8, 2021
P3, N=413, Completed, Sponsor: Ferring Pharmaceuticals
These findings are suggestive of distinct in vivo activities of these preparation, but require cautious interpretation and further validation from clinical studies. Active, not recruiting --> Completed
- | Rekovelle (follitropin delta) / Ferring
Preclinical, Journal: Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. (Pubmed Central) - Aug 4, 2021
P=N/A
Active, not recruiting --> Completed Optimizing the ovarian response during in vitro fertilization employing a mixed protocol of individualized dosing of follitropin delta and HP-hMG resulted in a statistically significant number of usable blastocysts on days 5 and 6 with an increased risk of mild OHSS, which did not require medical intervention or hospitalization.
- || Menopur (menotropin) / Ferring
Trial completion date, Trial initiation date, Trial primary completion date: A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women (clinicaltrials.gov) - Jul 14, 2021
P1, N=88, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Optimizing the ovarian response during in vitro fertilization employing a mixed protocol of individualized dosing of follitropin delta and HP-hMG resulted in a statistically significant number of usable blastocysts on days 5 and 6 with an increased risk of mild OHSS, which did not require medical intervention or hospitalization. Trial completion date: May 2022 --> Oct 2022 | Initiation date: Jun 2021 --> Oct 2021 | Trial primary completion date: May 2022 --> Oct 2022
- || Menopur (menotropin) / Ferring
Clinical, Journal: Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin. (Pubmed Central) - Jul 6, 2021
COH can be achieved in the setting of low positive hCG levels with subsequent successful oocyte maturation. The threshold for hCG trigger to be ineffective in the setting of a positive hCG has yet to be determined.
- || Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Clinical, Journal, HEOR: Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial. (Pubmed Central) - Jul 6, 2021
P4
Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. NCT02554279.
- || Menopur (menotropin) / Ferring
Clinical, Journal: Ovarian stimulation for fertility preservation in an oncology patient with etonogestrel implant in place. (Pubmed Central) - Jul 2, 2021
COH and successful oocyte cryopreservation can be achieved in patients with an etonogestrel implant in situ without apparent detrimental effects to oocyte yield or maturity. Due to the etonogestrel implant's inhibitory effects on LH, it is recommended to use an hCG trigger for final oocyte maturation.
- ||| Menopur (menotropin) / Ferring
Enrollment open: MEDAM (Menopur Retrospective Data prograM) (clinicaltrials.gov) - May 27, 2021
P=N/A, N=8126, Recruiting, Sponsor: Ferring Pharmaceuticals
Due to the etonogestrel implant's inhibitory effects on LH, it is recommended to use an hCG trigger for final oocyte maturation. Not yet recruiting --> Recruiting
- ||| Menopur (menotropin) / Ferring
New P1 trial: A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women (clinicaltrials.gov) - May 26, 2021
P1, N=88, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- |||||| Menopur (menotropin) / Ferring
New trial: MEDAM (Menopur Retrospective Data prograM) (clinicaltrials.gov) - May 5, 2021
P, N=8126, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- || Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Clinical, Journal: Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. (Pubmed Central) - Apr 20, 2021
P4
Not yet recruiting --> Recruiting In high responders, HP-hMG provided comparable efficacy to rFSH with fewer adverse events, including pregnancy loss, suggesting its optimized risk/benefit profile in this population.
- ||| Menopur (menotropin) / Ferring
Enrollment open, Real-world evidence, Real-world: Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment (clinicaltrials.gov) - Apr 8, 2021
P=N/A, N=1000, Recruiting, Sponsor: Ferring Pharmaceuticals
In high responders, HP-hMG provided comparable efficacy to rFSH with fewer adverse events, including pregnancy loss, suggesting its optimized risk/benefit profile in this population. Not yet recruiting --> Recruiting
- ||||| Menopur (menotropin) / Ferring
Enrollment closed: CLARA: Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Mar 28, 2021
P3, N=400, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| Menopur (menotropin) / Ferring
New trial, Real-world evidence, Real-world: Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment (clinicaltrials.gov) - Mar 23, 2021
P, N=1000, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- | Menopur (menotropin) / Ferring, Merional (menotropin) / IBSA Institute Biochemical SA, Bemfola (follitropin alfa biosimilar) / Gedeon Richter
Journal: Qualitative risk assessment of follicle stimulating hormone injectable products. (Pubmed Central) - Mar 2, 2021
Recruiting --> Active, not recruiting The study identifies differences in the risks for both sharps injuries and dosing errors between FSH delivery options that practitioners should consider when making a treatment choice.
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring, Cetrotide (cetrorelix) / EMD Serono
Enrollment closed, Trial completion date: CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) - Feb 23, 2021
P=N/A, N=200, Active, not recruiting, Sponsor: Lebanese University
The study identifies differences in the risks for both sharps injuries and dosing errors between FSH delivery options that practitioners should consider when making a treatment choice. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021
- || Menopur (menotropin) / Ferring, Follistim AQ Cartridge (follitropin beta) / Organon, Bravelle (urofollitropin) / Ferring
Biomarker, Trial primary completion date, Adverse events: HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - Feb 18, 2021
P4, N=890, Recruiting, Sponsor: Lund University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021 Trial primary completion date: Jun 2021 --> Dec 2020
- | Menopur (menotropin) / Ferring, Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
Trial completion: DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore (clinicaltrials.gov) - Dec 29, 2020
P=N/A, N=136, Completed, Sponsor: IVI Madrid
Trial primary completion date: Jun 2021 --> Dec 2020 Recruiting --> Completed
- Menopur (menotropin) / Ferring
[VIRTUAL] When effective medical treatment of a macroprolactinoma fails to correct infertility – a case report of a successful assisted reproduction approach () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_654;
However despite having normal gonadotropins levels, amenorrhea persisted, with no other obvious etiology. This functional hypothalamic amenorrhea “look alike” imposed a therapeutic challenge.
- |||| Menopur (menotropin) / Ferring
Trial completion date, Trial primary completion date: CLARA: Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Nov 5, 2020
P3, N=400, Recruiting, Sponsor: Ferring Pharmaceuticals
This functional hypothalamic amenorrhea “look alike” imposed a therapeutic challenge. Trial completion date: Jan 2022 --> Oct 2021 | Trial primary completion date: Nov 2021 --> Aug 2021
- |||| Menopur (menotropin) / Ferring
Trial completion date, Trial primary completion date: CLARA: Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Oct 26, 2020
P3, N=400, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial completion date: Jan 2022 --> Oct 2021 | Trial primary completion date: Nov 2021 --> Aug 2021 Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Nov 2021
- | New P3 trial: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (clinicaltrials.gov) - Sep 2, 2020
P3, N=80, Not yet recruiting, Sponsor: El Shatby University Hospital for Obstetrics and Gynecology
- | Menopur (menotropin) / Ferring
Trial completion: Mono-menotropins Versus rFSH Protocol on Embryo Quality (clinicaltrials.gov) - Aug 12, 2020
P=N/A, N=109, Completed, Sponsor: Main Line Fertility Center
Trial completion date: Sep 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Nov 2021 Recruiting --> Completed
- || Menopur (menotropin) / Ferring
Clinical: Menopur - FSH/LH injections so called because it's derived from purified menopausal women's urine Pop fact - it was originally made in large quantities by collecting the urine of Italian nuns from convents, as the Vatican had a large stake in Serono the drug company (Twitter) - Aug 5, 2020
- |||| Menopur (menotropin) / Ferring
Trial completion date, Trial primary completion date: CLARA: Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) (clinicaltrials.gov) - Jul 16, 2020
P3, N=400, Recruiting, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Nov 2020 --> Jul 2021